Stock Analysts’ Updated EPS Estimates for November 18th (ABUS, ACET, AKRO, ANY, APRE, ARCH, BEEM, BNTX, BSX, BTCY)

Stock Analysts’ updated eps estimates for Monday, November 18th:

Arbutus Biopharma (NASDAQ:ABUS) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $5.00 price target on the stock.

Adicet Bio (NASDAQ:ACET) had its neutral rating reissued by analysts at HC Wainwright.

Akero Therapeutics (NASDAQ:AKRO) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $50.00 target price on the stock.

Sphere 3D (NASDAQ:ANY) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $3.00 target price on the stock.

Aprea Therapeutics (NASDAQ:APRE) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $20.00 price target on the stock.

Arch Resources (NYSE:ARCH) had its buy rating reiterated by analysts at Benchmark Co.. Benchmark Co. currently has a $180.00 target price on the stock.

Beam Global (NASDAQ:BEEM) had its hold rating reaffirmed by analysts at Needham & Company LLC.

BioNTech (NASDAQ:BNTX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $150.00 target price on the stock.

Boston Scientific (NYSE:BSX) had its hold rating reaffirmed by analysts at Needham & Company LLC.

Biotricity (NASDAQ:BTCY) had its neutral rating reiterated by analysts at HC Wainwright.

Candel Therapeutics (NASDAQ:CADL) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $11.00 target price on the stock.

Chimerix (NASDAQ:CMRX) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $6.00 price target on the stock.

Cybin (NYSE:CYBN) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $190.00 target price on the stock.

Cytokinetics (NASDAQ:CYTK) had its buy rating reissued by analysts at HC Wainwright. They currently have a $120.00 price target on the stock.

Eyenovia (NASDAQ:EYEN) had its neutral rating reaffirmed by analysts at LADENBURG THALM/SH SH.

Fortive (NYSE:FTV) had its hold rating reaffirmed by analysts at Argus.

GEN Restaurant Group (NASDAQ:GENK) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $14.00 price target on the stock.

Gogoro (NASDAQ:GGR) had its hold rating reissued by analysts at Benchmark Co..

Global-E Online (NASDAQ:GLBE) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $48.00 target price on the stock.

Globant (NYSE:GLOB) had its hold rating reiterated by analysts at Canaccord Genuity Group Inc.. Canaccord Genuity Group Inc. currently has a $205.00 price target on the stock.

Medtronic (NYSE:MDT) had its hold rating reaffirmed by analysts at Needham & Company LLC.

MKS Instruments (NASDAQ:MKSI) had its buy rating reissued by analysts at Benchmark Co.. Benchmark Co. currently has a $142.00 price target on the stock.

Moderna (NASDAQ:MRNA) had its overweight rating reiterated by analysts at Piper Sandler. The firm currently has a $69.00 price target on the stock, down from their previous price target of $115.00.

Microvast (NASDAQ:MVST) had its buy rating reissued by analysts at HC Wainwright. HC Wainwright currently has a $3.00 price target on the stock.

Intellia Therapeutics (NASDAQ:NTLA) had its neutral rating reissued by analysts at Wedbush. The firm currently has a $14.00 price target on the stock.

Intellia Therapeutics (NASDAQ:NTLA) had its neutral rating reissued by analysts at William Blair. They currently have a $14.00 price target on the stock.

NVIDIA (NASDAQ:NVDA) had its buy rating reaffirmed by analysts at Rosenblatt Securities. The firm currently has a $200.00 price target on the stock.

RXO (NYSE:RXO) had its neutral rating reaffirmed by analysts at The Goldman Sachs Group, Inc.. They currently have a $29.00 price target on the stock.

Sweetgreen (NYSE:SG) had its buy rating reissued by analysts at TD Cowen. They currently have a $45.00 target price on the stock.

Summit Therapeutics (NASDAQ:SMMT) had its buy rating reissued by analysts at HC Wainwright. They currently have a $44.00 target price on the stock.

Spero Therapeutics (NASDAQ:SPRO) had its hold rating reissued by analysts at TD Cowen.

Surf Air Mobility (NYSE:SRFM) had its hold rating reissued by analysts at Canaccord Genuity Group Inc.. The firm currently has a $2.20 price target on the stock.

Sutro Biopharma (NASDAQ:STRO) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $12.00 price target on the stock.

Tesla (NASDAQ:TSLA) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $400.00 price target on the stock.

Zura Bio (NASDAQ:ZURA) had its neutral rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $5.00 target price on the stock.